Huimin Shen

Dr. Huimin Shen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in EBioMedicine
Verified
Journal Article
Open access
NJNan Jiang
Nan Jiang
GNGang Niu
Gang Niu
YPYing-Hua Pan
Ying-Hua Pan
WPWenwei Pan
Wenwei Pan
MZMei-Fang Zhang
Mei-Fang Zhang
HSHuimin Shen
Huimin Shen
Dysregulation of polycomb chromobox (CBX) proteins that mediate epigenetic gene silencing contributes to the progression of human cancers. Yet their roles in clear cell renal cell carcinoma (ccRCC) remain to be explored. The expression of CBX4 and its clinical significance were determined by qRT-PCR, western blot, immunohistochemistry and statistical analyses. The biological function of CBX4 in ccRCC tumor growth and metastasis and the underlying mechanism were investigated using in vitro and in vivo models. CBX4 exerts oncogenic activities in ccRCC via interaction with HDAC1 to transcriptionally suppress tumor suppressor KLF6. CBX4 expression is increased in ccRCC and correlated with poor prognosis in two independent cohorts containing 840 patients. High CBX4 expression is significantly associated with Fuhrman grade and tumor lymph node invasion. CBX4 overexpression promotes tumor growth and metastasis, whereas CBX4 knockdown results in the opposite phenotypes. Mechanistically, CBX4 downregulates KLF6 via repressing the transcriptional activity of its promoter. Further studies show that CBX4 physically binds to HDAC1 to maintain its localization on the KLF6 promoter. Ectopic expression of KLF6 or disruption of CBX4-HDAC1 interaction attenuates CBX4-mediated cell growth and migration. Furthermore, CBX4 depletion markedly enhances the histone deacetylase inhibitor (HDACi)-induced cell apoptosis and suppression of tumor growth. Our data suggest CBX4 as an oncogene with prognostic potential in ccRCC. The newly identified CBX4/HDAC1/KLF6 axis may represent a potential therapeutic target for the clinical intervention of ccRCC.

1 March 2020 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
NJNan Jiang
Nan Jiang
QLQiu-Li Li
Qiu-Li Li
WPWenwei Pan
Wenwei Pan
JLJinhui Li
Jinhui Li
MZMei-Fang Zhang
Mei-Fang Zhang
HSHuimin Shen
Huimin Shen

5 February 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
SSShu-Guang Su
Shu-Guang Su
QLQiu-Li Li
Qiu-Li Li
MZMei-Fang Zhang
Mei-Fang Zhang
PZPeng-Wei Zhang
Peng-Wei Zhang
HSHuimin Shen
Huimin Shen
CZChris Zhiyi Zhang
Chris Zhiyi Zhang
Hepatocellular carcinoma (HCC) accounts for one of the leading causes of cancer-related death, and is attributed to the dysregulation of genes involved in genome stability. DDX11, a DNA helicase, has been implicated in rare genetic disease and human cancers. Yet, its clinical value, biological function, and the underlying mechanism in HCC progression are not fully understood. Here, we show that DDX11 is upregulated in HCC and exhibits oncogenic activity via EZH2/p21 signaling. High expression of DDX11 is significantly correlated with poor outcomes of HCC patients in two independent cohorts. DDX11 overexpression increases HCC cell viabilities and colony formation, whereas DDX11 knockdown arrests cells at G1 phase without alteration of p53 expression. Ectopic expression of DDX11 reduces, while depletion of DDX11 induces the expression of p21. Treatment of p21 siRNA markedly attenuates the cell growth suppression caused by DDX11 silence. Further studies reveal that DDX11 interacts with EZH2 in HCC cells to protect it from ubiquitination-mediated protein degradation, consequently resulting in the downregulation of p21. In addition, E2F1 is identified as one of the upstream regulators of DDX11, and forms a positive feedback loop with EZH2 to upregulate DDX11 and facilitate cell proliferation. Collectively, our data suggest DDX11 as a promising prognostic factor and an oncogene in HCC via a E2F1/DDX11/EZH2 positive feedback loop.

30 November 2025 in Gut
Verified
Journal Article
Closed access
XWXiangguang Wu
Xiangguang Wu
MWMingfu Wu
Mingfu Wu
HLHuawen Li
Huawen Li
YYYang Yang
Yang Yang
HSHuimin Shen
Huimin Shen
WWWei Wang
Wei Wang
Background: Endometriosis is a debilitating gynaecological disorder with an elusive pathogenesis. While gut microbiota dysbiosis has been implicated, the causal role of gut-peritoneum microbial translocation and the specific mechanisms driving disease progression remain elusive. Notably, the role of peritoneal neutrophils and neutrophil extracellular traps (NETs) in the development of endometriosis remains unknown. Objective: This study aims to delineate the pathogenic pathway linking gut microbiota to peritoneal neutrophil activation and the development of endometriosis. Design: We combined single-cell RNA sequencing of clinical peritoneal fluid immune cells with functional validation in heterologous and homologous mice models. We further adopted microbial source-tracking analysis of patient cohorts and interventional strategies, including faecal microbiota transplantation (FMT) and administration of green fluorescent protein (GFP)-tagged Pseudomonas aeruginosa . Results: We identified a unique membrane metalloendopeptidase (MME) positive neutrophil subset (Neu_MME) that is expanded in endometriosis and primed for NETs formation (NETosis). These Neu_MME released NETs in response to bacterial lipopolysaccharides (LPS), which directly captured endometrial cells and enhanced their proliferation and migration, driving lesion development. Accordingly, inhibiting NETosis or degrading NETs significantly suppressed endometriosis in mice. Furthermore, FMT from patients with endometriosis to mice disrupted the intestinal barrier, promoting the translocation of gut microbiota, particularly Pseudomonas , into the peritoneal cavity and the lesions. This translocated Pseudomonas was identified as a key driver of LPS-induced NETosis and disease progression. Conclusion: Our findings define a gut-peritoneum axis in endometriosis, where gut-derived Pseudomonas triggers NETosis in peritoneal Neu_MME to promote disease, suggesting that targeting this bacterium or NETosis represents a viable therapeutic strategy.

16 June 2020 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
NJNan Jiang
Nan Jiang
WPWenwei Pan
Wenwei Pan
JLJinhui Li
Jinhui Li
TCTiefeng Cao
Tiefeng Cao
HSHuimin Shen
Huimin Shen

11 April 2025 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
HLHao-Yu Liang
Hao-Yu Liang
RLRong-Zhen Luo
Rong-Zhen Luo
RDRu Deng
Ru Deng
SCShi-Lu Chen
Shi-Lu Chen
XLXuan Liu
Xuan Liu
LLLi-Li Liu
Li-Li Liu